Lantheus Holdings Inc. is making waves in M&A with its second big deal of the month – and year – the acquisition of Evergreen Theragnostics Inc. for $250 million in cash up front and up to an additional $752.5 million in contingent payments. The transaction follows announcement of a definitive agreement to acquire Life Molecular Imaging Ltd., a subsidiary of Life Healthcare Group Holdings Ltd., on Jan. 13 for $350 million in cash at closing and a further $400 million in milestone payments.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: AI Optics, Beckman Coulter, Claritas, Fresenius Kabi, Instylla, Modella.
False Claims Act litigation in the U.S. spiked significantly according to a new report by Gibson, Dunn & Crutcher, LLP, at least in terms of the number of cases brought to the courts.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Ignite Proteomics, IMAC Holdings, Intelligent Bio, Ivy Diagnostics, Lucia Health, Paragonix Technologies, Polarean Imaging, Simonmed Imaging, Royal Philips.
Litigation against companies in the life sciences has far too often covered those who were not injured by the device or drug, but there are signs that this tide is shifting.
With multiple large M&A deals already announced in January, CEOs of major med-tech companies outlining acquisition plans for 2025 and declining interest rates, the stage is set for a significantly more active year of M&A. Financings, too, have ticked up and analysts expect the trend to continue, offering hope for a positive year for the med-tech industry.
The U.K.’s new postmarket monitoring requirements do not represent a sea change in device makers’ responsibilities in this area, but the expansions of responsibility are nonetheless significant.
RSS
